Effect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with type 1 diabetes
Authors' conclusion
The protective mechanisms of SGLT2 inhibition on blood pressure, RAAS activation, and renal hemodynamics are apparent in the subset of people with uncomplicated T1D with adverse cardiorenal and inflammatory markers.
Study context
- Population
- Adults with uncomplicated T1D (clamp trial: 49 with T1D and 27 controls; BETWEEN trial: 30 with T1D)
- Comparison
- Acute hyperglycemia vs euglycemia (clamp); empagliflozin 25 mg + ramipril vs placebo-ramipril for 4 weeks (BETWEEN)
- Empagliflozinn = 30
- Placebon = 30reference
Methodological detailsglycemic clamp trial and crossover BETWEEN trial, placebo-controlled (BETWEEN trial)
- Glycemic clamp trial and crossover BETWEEN trial
- Placebo-controlled (BETWEEN trial)
Primary result
As reported in the abstract
Serum cardiac, kidney injury, inflammatory and hemodynamic markers
- Hyperglycemia vs Euglycemia: P = 0.0003
- Hyperglycemia vs Euglycemia: P = 0.003
- Empagliflozin vs Placebo-ramipril: P = 0.0147
- Post-hoc
Further findings
Baseline markers and empagliflozin response (BETWEEN)
- Higher baseline sST2 and sTNFR1: greater empagliflozin-associated systolic BP reductions and greater renin-angiotensin-aldosterone system (RAAS) mediator activation
- Higher baseline KIM-1 and sTNFR1: greater glomerular filtration rate (GFR) dip
Original publication
Effect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with type 1 diabetes. Diabetes Res Clin Pract. Published 2 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →